文献速递毛发、甲与色素性疾病

Deucravacitinib治疗斑秃的II期随机对照试验疗效与安全性结果

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicentre, randomized, double-blinded, placebo-controlled trial.
PubMed 文献 · Br J Dermatol · 2026-01-01

这项II期多中心随机双盲安慰剂对照试验纳入94例斑秃患者,评估口服选择性变构TYK2抑制剂deucravacitinib的疗效与安全性。第24周时,deucravacitinib 6mg每日一次组SALT评分较基线变化与安慰剂组无显著差异,6mg每日两次组差异有统计学意义但未达主要终点,所有次要终点均无差异。试验因申办方战略决策提前终止,未发现新安全性信号。

要点

  • Deucravacitinib 6mg每日一次组第24周SALT评分变化与安慰剂无显著差异。
  • 6mg每日两次组SALT评分变化差异有统计学意义,但未达主要疗效终点。
  • 所有次要终点均无差异,未发现新安全性信号。

核心结论

  • 本试验未达到疗效终点,deucravacitinib抑制TYK2可能对斑秃患者毛发再生不起主要作用。
  • Deucravacitinib在斑秃患者中的安全性与该TYK2抑制剂的已知安全性特征一致。

研究设计与样本

  • II期多中心随机双盲安慰剂对照试验,94例斑秃患者按1:1:1随机接受口服安慰剂、deucravacitinib 6mg每日一次或6mg每日两次。
  • 第24周时安慰剂组患者按1:1重新随机接受deucravacitinib 6mg每日一次或每日两次至第52周。
  • 主要疗效终点为第24周SALT评分较基线的变化。
  • 试验在第24周数据库锁定后、主要数据读出前因申办方战略决策终止,非因观察到或预期的疗效或安全性发现,提前终止未影响研究把握度。

主要发现

  • 第24周SALT评分较基线变化:deucravacitinib 6mg每日一次组调整均数差1.5(95%CI -6.2至9.2,P=0.701),6mg每日两次组调整均数差8.2(95%CI 0.2至16.2,P=0.045)。
  • 所有次要终点均未观察到差异。
  • 未发现新的安全性信号。
  • 52周内6例接受deucravacitinib治疗的患者达到SALT评分≤20。
  • Deucravacitinib最常见副作用为感冒症状、痤疮和毛囊炎,发生严重副作用或因此停药的患者数较少。

关键数值与推荐

  • 主要疗效终点为第24周SALT评分较基线的变化。
  • 次要终点包括第24周达到SALT评分较基线降低≥50%(SALT 50)的患者比例、SALT评分≤20的患者比例、以及斑秃研究者总体评估评分为0(清除)或1(几乎清除)且较基线改善≥2分的患者比例。

临床怎么用

  • 对于斑秃患者,deucravacitinib 6mg每日一次或每日两次治疗24周未显示优于安慰剂的毛发再生疗效。
  • Deucravacitinib在斑秃患者中的安全性与该药已知安全性特征一致。

局限性

  • 试验因申办方战略决策提前终止,尽管未影响研究把握度。
  • 样本量较小(共94例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alopecia areata (AA) is a common, immune-mediated inflammatory disease characterized by nonscarring hair loss. Tyrosine kinase (TYK)2 mediates signalling of select proinflammatory cytokines [e.g. interleukin (IL)-12, IL-23 and type I interferons], which may play a role in the pathogenesis of AA. OBJECTIVES: To evaluate the efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with AA. METHODS: Patients were randomized 1 : 1 : 1 to oral placebo, deucravacitinib 6 mg once daily, or deucravacitinib 6 mg twice daily. At week 24, patients randomized to placebo were rerandomized 1 : 1 to deucravacitinib 6 mg once daily or deucravacitinib 6 mg twice daily until week 52. The primary efficacy endpoint was change from baseline in Severity of Alopecia Tool (SALT) score at week 24. Secondary endpoints were proportions of patients achieving ≥ 50% reduction from baseline in SALT score (SALT 50), SALT score ≤ 20, and Alopecia Areata Investigator Global Assessment score of 0 (clear) or 1 (almost clear) with ≥ 2-point improvement from baseline at week 24. This trial was terminated following database lock at week 24, but before primary data readout, owing to a strategic decision by the sponsor and not as a result of any observed, expected or perceived efficacy or safety findings with deucravacitinib treatment. Early termination did not affect study power. RESULTS: In total, 94 patients received placebo (n = 31), deucravacitinib 6 mg once daily (n = 32), or deucravacitinib 6 mg twice daily (n = 31). Baseline disease characteristics were balanced across treatment groups. No meaningful difference in change from baseline in SALT score at week 24 was observed between the deucravacitinib and placebo groups [6 mg once daily: adjusted mean difference 1.5, 95% confidence interval (CI) -6.2 to 9.2, P = 0.701; 6 mg twice daily: 8.2, 95% CI 0.2-16.2, P = 0.045]. Similarly, no differences were observed for any secondary endpoint. No new safety signals were identified. CONCLUSIONS: This trial did not meet the efficacy endpoints and TYK2 inhibition by deucravacitinib may not play a major role in hair regrowth in patients with AA. The safety of deucravacitinib in patients with AA was consistent with the known safety profile of this TYK2 inhibitor. Alopecia areata (AA) is a common inflammatory disease that causes hair loss. Living with symptoms of AA can be difficult. Some individuals may experience anxiety, depression and poor quality of life. Although current treatments can improve hair regrowth in some people, results are variable. Deucravacitinib is an approved oral medicine for AA. It works by blocking an enzyme involved in inflammation called tyrosine kinase (TYK)2. Early studies suggested that blocking TYK2 with deucravacitinib may be an effective treatment for AA. In this trial, we evaluated the safety and effect of deucravacitinib on hair regrowth in patients with AA. The trial was stopped early because of a business decision by the manufacturer. It was not stopped as a result of any observed, expected, or perceived efficacy or safety findings with deucravacitinib. In total, 94 patients with AA received placebo, deucravacitinib 6 mg once daily, or deucravacitinib 6 mg twice daily for 24 weeks. Patients receiving placebo were switched to deucravacitinib 6 mg once daily or 6 mg twice daily for an additional 28 weeks. We evaluated treatment responses using the Severity of Alopecia Tool (SALT). This tool measures scalp hair loss on a scale of 0 (none) to 100 (complete). We found no differences in treatment response at week 24 between the placebo group and either dose of deucravacitinib. We also found that six patients treated with deucravacitinib achieved a SALT score ≤ 20 over 52 weeks. The most common side effects with deucravacitinib were cold symptoms, acne and inflammation of hair follicles. The number of patients with serious side effects or stopping treatment because of side effects was low. Overall, this trial did not meet its efficacy objective. TYK2 inhibition by deucravacitinib may not play a major role in hair regrowth. However, the safety of deucravacitinib for people with AA was consistent with the known safety profile of this TYK2 inhibitor.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. King B, Ehst B, Foley P, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicentre, randomized, double-blinded, placebo-controlled trial. Br J Dermatol. 2026. PMID: 41905775. doi:10.1093/bjd/ljag109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。